← Clinical Trials
Arthroplasty, Replacement, Hip NA Registry Results NCT02525627

A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads: Complete Statistical Analysis

The registry record describes a randomized comparison of polyethylene insert wear with 28 mm and 40 mm metal femoral heads. It lists the intended wear assessment but reports no measured wear data or analysis results.

Trial start: 2010-10  ·  Enrollment: 40  ·  Sponsor: Stryker Orthopaedics
Scope of this record

This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.

1. Trial at a Glance

This page covers the registry results for A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads (NCT02525627), a randomized na study. The primary outcome is To Compare Wear of the Polyethylene X3 Insert Based on Digital Radiographs Using the Hip Analysis Suite (HAS)..

40
Enrollment
NA
n/a
Arms
In the primary outcome
n/a
Effect
No re-analysis shown
n/a
95% CI
See limitations
FeatureRegistry value
ClinicalTrials.gov identifierNCT02525627
PhaseNA
ConditionArthroplasty, Replacement, Hip
AllocationRandomized
Design modelParallel
MaskingSingle
Enrollment40
Arms in the primary outcomen/a
Lead sponsorStryker Orthopaedics
Results postedYes

2. Clinical Question

The clinical question concerns whether wear of the X3 polyethylene insert differs between the 28 mm and 40 mm metal femoral head groups after 5 years of follow-up. The registry describes the aim as determining equality of wear, using measurements from digital radiographs analyzed with the Hip Analysis Suite (HAS). The record does not report a wear estimate or an analysis comparing the groups, so it does not establish whether wear was equal or different.

Population

People receiving hip replacement for the condition listed as arthroplasty, replacement, hip. The registry describes a prospective, single-centre study and an evaluation period of 5 years. The actual analysis population is not reported in the registry record.

Intervention

A Trident cup with an X3 insert and a 40 mm metal femoral head. The registry also lists Symax and Accolade TMZF stems as devices used in the study; it does not describe a separate comparison of stem types.

Comparator

A Trident cup with an X3 insert and a 28 mm metal femoral head. The arm descriptions list the same two possible stem types as for the 40 mm group: Symax or Accolade TMZF.

Primary question

Does polyethylene wear, assessed from digital radiographs using HAS at 5 years, differ between the 28 mm and 40 mm head groups? The registry does not report the wear data or an answer to this question.

3. Trial Design

The record describes a prospective, single-centre, randomized clinical study with a parallel-group model and single masking. It lists the study status as terminated. Enrollment is recorded as 40, but the record does not explain whether this figure represents a target or the number actually enrolled. The primary completion date is listed as 2016-01-12; the study start is listed as 2010-10.

The comparison is between a Trident cup with an X3 acetabular polyethylene insert and a 28 mm metal head, and the same cup-and-insert combination with a 40 mm metal head. Both arm descriptions also list the Symax stem or Accolade TMZF stem. The registry does not report how participants were assigned between these stem options, or whether stem choice was balanced between the head-size groups.

The stated patient evaluation period is 5 years. The primary outcome description specifies wear assessment at 5 years using digital radiographs and HAS software. The registry also lists the Harris Hip Score patient questionnaire and Merle D'Aubergine Score as secondary outcomes. It does not give results for these measures.

Although the trial is described as randomized, details of sequence generation, allocation concealment, masking procedures, and the groups of people who were masked are not reported in the registry record. The record does not state why the study was terminated or whether termination affected recruitment, follow-up, or data collection. These omissions limit what can be concluded about how the planned comparison was conducted.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 40 participants/hips - 6 participants/hips excluded during surgery = 34 participants/hips

Overall Study

StageTrident Cup, X3 Inserts, 28 mm HeadTrident Cup, X3 Inserts, 40 mm Head
STARTED1618
COMPLETED25
NOT COMPLETED1413

Reasons for not completing this period:

ReasonTrident Cup, X3 Inserts, 28 mm HeadTrident Cup, X3 Inserts, 40 mm Head
Revision11
Withdrawal by Subject12
Death10
Site terminated1110

Analysis population for the primary outcome, as defined in the registry: Wear data were not measured at the investigation site.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

CharacteristicUnitTrident Cup, X3 Inserts, 28 mm HeadTrident Cup, X3 Inserts, 40 mm HeadTotal
Participants analysed161834
Age, Continuousyears66.67 (SD 4.68)62.91 (SD 6.25)64.68 (SD 5.87)
Sex: Female, Male: FemaleParticipants81018
Sex: Female, Male: MaleParticipants437
Region of Enrollment: Netherlandsparticipants161834

6. Primary Endpoint

The registry lists the primary outcome as To Compare Wear of the Polyethylene X3 Insert Based on Digital Radiographs Using the Hip Analysis Suite (HAS)., measured over 5 years follow-up.

ElementRegistry entry
Result typeN/A
Measure of spreadnot applicable
Unitnot stated
Endpoint classificationnot reduced to a single comparison

The primary outcome is described as wear of the X3 polyethylene insert assessed from digital radiographs with the Hip Analysis Suite (HAS), at 5 years of follow-up. HAS is identified in the record as software for determining polyethylene wear on digital radiographs. The registry does not specify a unit, a statistical parameter, a measure of dispersion, a threshold for a clinically meaningful difference, or a precise definition of the wear measure.

In general, an imaging-based wear measure provides a way to quantify change in the position or appearance of an implant component over time. A standardized software method can support consistent measurement from radiographs, but the meaning of the result depends on the measurement definition, image quality, timing, and analysis procedures. Those details are not reported in the registry record.

The outcome is intended to compare wear between the head-size groups, rather than to report a patient-reported score. The question is framed as whether wear is equal at the 5-year assessment. The record states, however, that wear data were not measured at the investigation site. It includes no group estimates, uncertainty intervals, or inferential analysis for this endpoint. Therefore the endpoint description explains the intended measurement, but cannot be used to determine the observed wear or the result of the comparison.

7. Why No Re-analysis Is Shown

Reported as posted, not recalculated. Primary outcome has several categories or time points; not reduced to one comparison. A result is recalculated only when the posted data support a clean two-arm comparison, so no result is shown beyond what the sponsor posted.

8. Statistical Interpretation

Clinical Biostats interpretation

The registry record identifies a randomized comparison of the 28 mm and 40 mm metal head groups, with wear of the X3 insert as the primary outcome. It does not report measured wear data. The primary outcome entry says that wear data were not measured at the investigation site, and the record lists no analysis records. As a result, there is no posted estimate of the difference between groups, no confidence interval, and no p-value for the primary wear comparison.

This is not evidence that the groups had equal wear. Nor does the record show that one group had more wear. An equality question requires observed data and a specified analysis capable of assessing how compatible those data are with equality and with differences of relevant size. Without the wear measurements and the analysis, the direction, magnitude, and precision of the comparison cannot be evaluated.

The registry gives a 5-year follow-up timeframe and describes HAS analysis of digital radiographs. These details define the intended endpoint and timing, but they do not substitute for outcome values. The listed secondary outcomes are the Harris Hip Score patient questionnaire and Merle D'Aubergine Score. Their results are not reported in the registry record either.

The adverse-event entry is separate from the missing wear result. It lists serious adverse-event figures for each group, and lists zero other adverse events in each group. These safety counts do not answer the primary wear question. The record does not provide enough detail to determine whether the listed serious events were related to the devices, how events were defined or collected, or how follow-up differed among participants.

The study status is terminated, but the reason for termination and its implications for outcome collection are not reported. Enrollment is recorded as 40, while the number included in the wear assessment and any reasons for missing data are also not reported. These gaps prevent a complete assessment of the intended randomized comparison. The registry supports a description of the design and planned outcome, but not a conclusion about comparative wear or patient-reported outcomes.

9. Statistical Methods Explained

The record describes random allocation, a parallel-group model, and single masking. These labels describe broad features of a trial design, not the detailed procedures used to carry it out. In general, random allocation is intended to reduce systematic differences between treatment groups at the start of a study. A parallel design compares groups receiving different interventions during the same study period. The record does not describe the randomization sequence, concealment of assignments, or masking procedures, so those aspects cannot be assessed.

What would the primary comparison estimate?

In general, a comparative endpoint can be analyzed by estimating the outcome in each group and then estimating a contrast between groups. For a continuous wear measure, that contrast might be based on group means or another prespecified summary, depending on the outcome distribution and analysis plan. The registry does not identify the wear unit, the statistical parameter, or the planned contrast. It reports no wear values or analysis results, so there is no estimate to interpret.

A confidence interval, in general, describes the range of effect values compatible with the observed data under the model and method used. It reflects statistical uncertainty, not the probability that a particular effect is true. A narrow interval indicates greater precision than a wide interval, while either interval may include values with different practical interpretations. No interval for the primary endpoint is reported in the registry record.

A p-value, in general, describes how unusual data at least as extreme as those observed would be under a specified null hypothesis and statistical model. It does not measure the size or practical importance of an effect. Because the record contains no reported primary analysis, it offers no p-value with which to assess the wear comparison. The equality wording in the aim is not itself a statistical result.

How should the planning assumptions be read?

The record describes a planning illustration based on an observed effect, using a two-sided significance level of 0.05, equal allocation, and a normal approximation. It says that the effect to detect is a stated fraction of the observed effect. These are described as planning assumptions, not as the trial's own design rationale. The registry does not report the trial's sample-size justification or statistical plan.

In general, a sample-size calculation estimates the amount of information needed for a proposed analysis under stated assumptions. It is not an observed result, and it does not show the probability that a completed study found an effect. A planning illustration based on an observed effect can be especially difficult to interpret when the underlying endpoint estimate and analysis are not reported. It should not be described as observed power, and it cannot fill the gap left by missing wear results.

The record specifies that time-to-event planning illustrations use a total event count based on the Schoenfeld method, while other illustrations are expressed as participants per arm. It does not identify the primary endpoint as a time-to-event outcome, and it does not report a primary wear analysis. The statistical assumptions therefore do not establish how wear was measured or analyzed.

Why do measurement and follow-up details matter?

In general, repeated imaging measurements can be affected by image quality, positioning, measurement reproducibility, and the timing of assessments. A prespecified measurement procedure can help reduce inconsistent interpretation, while a documented analysis plan can clarify how repeated observations and missing images are handled. The registry names digital radiographs and HAS, but these procedural details are not reported.

The stated follow-up timeframe is 5 years. For an endpoint intended to be assessed at a fixed follow-up, it matters whether the groups have comparable availability of measurements at that time and how participants without an assessment are handled. The registry does not report the number with available wear data, reasons for missingness, or an analysis population. Without those details, precision and potential bias in any comparison cannot be evaluated.

General statistical interpretation requires both an estimate and information about its uncertainty, together with enough description of the analysis to understand what population and outcome the estimate represents. The registry provides the intended comparison and some design labels, but not the wear measurements, estimates, uncertainty, or analysis procedures. Accordingly, the statistical methods described in the record are insufficient to reconstruct or assess the primary endpoint analysis.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists the primary wear outcome and two secondary outcomes: the Harris Hip Score patient questionnaire and Merle D'Aubergine Score. It does not report an analysis for any of them. The record does not describe a hierarchy among outcomes, adjustment for multiple comparisons, or a prespecified approach to controlling the chance of false-positive findings when several outcomes or analyses are considered. These procedures are not reported in the registry record.

In general, multiplicity arises when several hypotheses, outcomes, time points, or subgroup comparisons are tested. Repeated testing can increase the chance that at least one result appears statistically notable by chance. A prespecified hierarchy or multiplicity adjustment can help make interpretation more transparent. Without a reported analysis plan or results, it is not possible to determine whether multiplicity was relevant to the analyses actually conducted or how it was addressed.

The primary outcome entry refers to a 5-year follow-up, while the record notes that the outcome has several categories or time points and was not reduced to one comparison. It does not explain those categories or time points, or provide estimates for them. The record does not report missing-data methods, the number of participants with outcome measurements, or the analysis population. It also does not state whether the analysis followed randomized assignment or used another population definition.

In general, missing outcome data can reduce precision and can bias a comparison if availability is related to group assignment or outcome values. The direction and size of any such effect depend on the missingness pattern and analysis method. Since neither is reported, no assessment of missing-data bias is possible. The termination status makes it especially important to know whether follow-up and outcome collection were completed as planned, but the record does not report the reason for termination or its effect on missingness.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

ArmParticipants with serious adverse eventsParticipants at riskPercentage
Trident Cup, X3 Inserts, 28 mm Head61637.5%
Trident Cup, X3 Inserts, 40 mm Head21811.1%
Participants with at least one serious adverse event
Serious adverse events by armTrident Cup, X3 Inserts, 28 m…37.5%Trident Cup, X3 Inserts, 40 m…11.1%% of participants with at least one serious adverse event

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

ArmParticipants affected of at risk
Trident Cup, X3 Inserts, 28 mm Head0 of 16
Trident Cup, X3 Inserts, 40 mm Head0 of 18

Most frequent serious adverse event terms

Event termOrgan systemTrident Cup, X3 Inserts, 28 mm HeadTrident Cup, X3 Inserts, 40 mm Head
Luxation of hip prosthesisMusculoskeletal and connective tissue disorders1 of 161 of 18
Bladder TumorNeoplasms benign, malignant and unspecified (incl cysts and polyps)1 of 160 of 18
Bowel CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1 of 160 of 18
Cardiac ArrhythmiaCardiac disorders1 of 160 of 18
Intraoperative Trochanter FractureMusculoskeletal and connective tissue disorders1 of 160 of 18
Lung carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0 of 161 of 18
Superficial infectionInfections and infestations1 of 160 of 18

Serious events with the highest arm-level rate: luxation of hip prosthesis (6.2%), bladder tumor (6.2%), bowel cancer (6.2%), cardiac arrhythmia (6.2%), intraoperative trochanter fracture (6.2%).

Do not overextend the safety comparison. Serious-adverse-event counts are safety observations, not efficacy outcomes, and should not be combined with the primary result into a single benefit-risk number.

The registry lists serious adverse-event figures for the 28 mm group as 6 affected among 16 at risk, and for the 40 mm group as 2 affected among 18 at risk. It lists zero other adverse events among 16 at risk in the 28 mm group and zero among 18 at risk in the 40 mm group. These are the figures recorded for the groups; the record does not explain how the risk sets were defined or whether the counts represent people, events, or another reporting unit.

The record lists serious terms including luxation of hip prosthesis, bladder tumor, bowel cancer, cardiac arrhythmia, intraoperative trochanter fracture, and superficial infection, each with 6.2%. It does not give a term-by-group breakdown or explain whether a person could contribute to more than one term. Death information is not reported in the registry record.

In general, safety counts need context: event definitions, observation periods, ascertainment procedures, exposure, and attribution all affect interpretation. The registry does not report whether events were judged related to treatment or how long participants were observed for adverse events. These figures alone do not establish causation or provide a complete comparison of safety between groups.

12. What the Result Does, and Does Not, Mean

The record supports a description of the intended clinical comparison: wear of a Trident cup X3 insert with a 28 mm metal head versus a 40 mm metal head, assessed using digital radiographs and HAS at 5 years. It also identifies a prospective, single-centre randomized study and lists patient-reported secondary outcomes. These registry entries describe the study's design and aims, not the outcome of the comparison.

The key limitation for interpretation is that wear data were not measured at the investigation site, according to the primary outcome entry. No primary analysis is listed. Therefore, the record does not show whether wear differed, how large any difference was, or how precise an estimate might be. It cannot support a conclusion of equality or a conclusion that one head size had greater wear.

The listed secondary outcomes do not resolve this gap because their results are not reported. Likewise, the adverse-event figures address safety reporting, not polyethylene wear. The record does not give enough context to attribute those events to a device or compare event risk in a fully informed way.

In general, a null or nonsignificant test would not by itself establish equivalence. An equivalence conclusion requires a prespecified margin defining how much difference is acceptable, an appropriate design and analysis, and estimates precise enough to exclude differences beyond that margin. The registry does not report an equivalence margin or an analysis. Its aim uses equality language, but that wording alone does not establish an equivalence test.

The appropriate reading is therefore limited: the registry documents the planned question and some trial characteristics, but it does not report the evidence needed to answer that question. The study's terminated status is recorded, but the reason and its consequences for data collection are not reported. The available record cannot establish the comparative performance of the head-size groups.

13. Why This Trial Matters Statistically

This trial is statistically notable because its stated primary question is a comparison of wear between two femoral head sizes, yet the primary outcome entry says wear data were not measured at the investigation site. The registry lists no analysis records. This distinction matters: a detailed intervention description and a clearly stated endpoint do not provide an estimate of the endpoint itself.

The record also illustrates why the wording of a research aim should be separated from the statistical claim that can be supported. The aim refers to determining equality of 5-year wear. In general, demonstrating equivalence requires a defined margin and an analysis designed to assess whether the uncertainty around the estimated difference falls within that margin. Neither a margin nor an equivalence analysis is reported. Equality cannot be inferred from the absence of a reported difference.

Randomization is an important design feature in general because it can support a fair comparison when allocation and follow-up are implemented appropriately. Here, the registry does not report the allocation procedures, outcome data, analysis population, or missing-data handling. Without those details, the randomization label alone cannot establish the strength or precision of the intended comparison.

The entry also lists planning assumptions based on an observed effect. Such illustrations are planning tools, not observed power and not substitutes for the primary analysis. When the primary outcome estimate and its uncertainty are absent, readers cannot assess how well the study addressed its intended question. The statistical significance of this record lies in that boundary: it documents a randomized comparison and planned measurement, but does not report the results needed to interpret comparative wear.

14. Limitations

The registry's primary outcome description states that wear data were not measured at the investigation site. No group-level wear estimates, uncertainty measures, or analysis results are listed. The outcome's unit, statistical parameter, and measure of dispersion are also not specified. These omissions prevent evaluation of the primary comparison's magnitude, precision, and direction.

Enrollment is recorded as 40, but the record does not clarify whether this is planned or actual enrollment. It does not report how many participants were included in each outcome analysis, how many had images at the 5-year assessment, or why any measurements were unavailable. The study is listed as terminated, but the reason for termination and its effect on recruitment, follow-up, and outcome collection are not reported.

The record describes randomization and single masking without giving the procedures used. It does not identify who was masked, how the allocation sequence was generated or concealed, or how the imaging assessments were standardized and reviewed. The use of HAS is named, but measurement reliability and analysis procedures are not described.

The arm descriptions allow either Symax or Accolade TMZF stems, but the record does not explain their use or distribution across groups. It also does not report an analysis plan, an equivalence margin, multiplicity procedures, or missing-data methods. Secondary outcome results are not reported. For safety, event definitions, attribution, observation duration, and death information are absent. Together, these limitations mean the registry record offers a limited account of trial conduct and no interpretable result for the main wear comparison.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

Continue through the Clinical Biostats statistical pathway

Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.

18. Record Summary

The registry record describes a prospective, single-centre randomized parallel-group study with single masking, comparing a Trident cup and X3 insert with 28 mm versus 40 mm metal heads. It lists enrollment as 40, a 5-year patient evaluation period, and a terminated status. The primary outcome is wear assessed from digital radiographs using HAS at 5 years. The record states that wear data were not measured at the investigation site and lists no analyses. The Harris Hip Score patient questionnaire and Merle D'Aubergine Score are named as secondary outcomes, without reported results. Serious adverse-event figures are listed by group, but event attribution and other safety context are not reported. The reason for termination, analysis population, and missing-data handling are not reported in the registry record.

Need an analysis like this for your own study?

Our team supports biostatistics, statistical programming and pharmacometric analyses. Send us a request and we will reply by email.

Request an analysis
Clinical Biostats